|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
EPFL Innovation Park Building B,Lausanne,Vaud,CH
|
|
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer’s disease. The Company’s pipeline features seven therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Abeta antibody in Phase 3 clinical studies, that is being advanced by our collaboration partner Genentech, Inc., a member of the Roche group. Other partners include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Science and Piramal Imaging.
|
AC Immune Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
100%
|
The widely used AC Immune email format is {first}.{last} (e.g. [email protected]) with 100% adoption across the company.
To contact AC Immune customer service number in your country click here to find.
Andrea Pfeifer is the CEO of AC Immune. To contact Andrea Pfeifer email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.